<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627923</url>
  </required_header>
  <id_info>
    <org_study_id>0694-17-RMC</org_study_id>
    <nct_id>NCT03627923</nct_id>
  </id_info>
  <brief_title>Personalizing Mediterranean Diet in Children.</brief_title>
  <official_title>Personalizing Mediterranean Diet in Children: the Ferrero Pilot Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schneider Children's Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Naples</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weizmann Institute of Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating glucose response to Mediterranean and regular diets in healthy children in&#xD;
      order to develop specific pediatric machine-learning for predicting the personalized glucose&#xD;
      response to food for individual children.&#xD;
&#xD;
      The prediction will be based on multiple measurements, including blood tests, personal&#xD;
      lifestyle and gut microbiome. This will allow investigators to design personalized&#xD;
      Mediterranean machine-learning-based diets which may potentially reduce the burden of disease&#xD;
      in adulthood as well as the burden of obesity in the pediatric age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early-life nutrition plays a critical role in mid-term and long-term metabolic and&#xD;
      nutritional outcomes. However, the mechanisms underlying the effects of early nutrition on&#xD;
      health are yet to be fully understood. Recently, it has been shown that alterations in&#xD;
      intestinal microbiota and modulation of the immune response induced by food serve as the main&#xD;
      mechanisms involved in the development of inflammatory conditions such as asthma,&#xD;
      inflammatory bowel diseases, and cardiovascular disease. The Mediterranean diet has been&#xD;
      shown to reduce the risk of cardiovascular disease, cancer, depression, colorectal cancer,&#xD;
      diabetes, obesity, asthma, cognitive decline and premature death in general. Some studies&#xD;
      also reported a positive effect of Mediterranean diet on glycemic control. However, whether&#xD;
      this diet is a benefit to all individuals is unknown. Likewise, whether gut microbiome and&#xD;
      its responses to diet is involved in these effects, or whether different Mediterranean diets&#xD;
      may be optimized at the individualized level remains unstudied.&#xD;
&#xD;
      Recently, the investigators developed an algorithm enabling to predict the personalized&#xD;
      postprandial glucose responses to food in adult healthy individuals. However, personalized&#xD;
      nutrition was never tested on children.&#xD;
&#xD;
      In this study, children will be followed up in different bio-geographical locations. The&#xD;
      primary aim of the study is to develop specific pediatric algorithms for predicting the&#xD;
      personalized glucose response to food for individual children. This prediction will be based&#xD;
      on multiple measurements, including blood and urine tests, anthropometric measurements,&#xD;
      personal lifestyle and gut microbiome. This may allow the investigators to design&#xD;
      personalized Mediterranean algorithm-based diets which may potentially reduce the burden of&#xD;
      non-communicable disease in adulthood as well as the burden of obesity in the pediatric age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial glycemic response</measure>
    <time_frame>1-3 years</time_frame>
    <description>Continuous glucose monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome composition and function</measure>
    <time_frame>1-3 years</time_frame>
    <description>Stool and urine samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood lipid profile</measure>
    <time_frame>1-3 years</time_frame>
    <description>Blood tests</description>
  </other_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Personalized Nutrition In Children</condition>
  <condition>Glucose, High Blood</condition>
  <condition>Diet Habit</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, stool and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy children will be invited to volunteer for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy children&#xD;
&#xD;
          -  6-11 years of age&#xD;
&#xD;
          -  Tanner 1&#xD;
&#xD;
             • Exclusion criteria:&#xD;
&#xD;
          -  Acute disease 2 months prior to enrollment&#xD;
&#xD;
          -  Chronic illness in the past 5 years, including inflammatory, metabolic, neoplastic,&#xD;
             congenital and infectious disease.&#xD;
&#xD;
          -  Use of medications (e.g. Antibiotics/antifungal, PPI, analgesics) and any antibiotics&#xD;
             3 months prior to the first visit, PPI one month prior to the beginning of the study&#xD;
             or use of medication during the study.&#xD;
&#xD;
          -  Treatment with anti-diabetic medications;&#xD;
&#xD;
          -  Neuro-psychiatric disorders&#xD;
&#xD;
          -  Cancer and recent anticancer treatment&#xD;
&#xD;
          -  Eating disorders (Anorexia nervosa. Bulimia nervosa. Binge eating disorder, Night&#xD;
             eating syndrome).&#xD;
&#xD;
          -  Inability of the participant and/or nuclear family to follow and utilize the&#xD;
             smartphone application.&#xD;
&#xD;
          -  Dietary restrictions or specific dietary regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Elinav, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weizmann Institute of Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurelie Bukimer Mimran</last_name>
    <phone>+97289529089</phone>
    <email>aurelie.bukimer@weizmann.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shimrit Eliyahu miller</last_name>
    <phone>+97289529089</phone>
    <email>shimrit.miller@weizmann.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weizmann Institute of Science</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aurelie Bukimer mimran</last_name>
      <phone>+97289529089</phone>
      <email>aurelie.bukimer@weizmann.ac.il</email>
    </contact>
    <contact_backup>
      <last_name>Shimrit Eliyahu miller</last_name>
      <phone>++97289529089</phone>
      <email>shimrit.miller@weizmann.ac.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weizmann Institute of Science</investigator_affiliation>
    <investigator_full_name>Eran Elinav</investigator_full_name>
    <investigator_title>Prof. Eran Elinav</investigator_title>
  </responsible_party>
  <keyword>Postprandial glucose response</keyword>
  <keyword>Mediterranean diet</keyword>
  <keyword>Personalized nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

